AIM ImmunoTech Inc’s stock (AIM) continues to rise above its goal

A share price of AIM ImmunoTech Inc [AIM] is currently trading at $2.45, down -3.66%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AIM shares have lost -9.26% over the last week, with a monthly amount drifted -16.10%, and not seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

AIM ImmunoTech Inc experienced fluctuations in its stock price throughout the past year between $2.33 and $37.80. AIM ImmunoTech Inc [AMEX: AIM] shares were valued at $2.45 at the most recent close of the market.

Analyzing the AIM fundamentals

Trailing Twelve Months sales for AIM ImmunoTech Inc [AMEX:AIM] were 0.12M which represents -50.00% decline. Gross Profit Margin for this corporation currently stands at 1.19% with Operating Profit Margin at -137.26%, Pretax Profit Margin comes in at -133.6%, and Net Profit Margin reading is -133.6%. To continue investigating profitability, this company’s Return on Assets is posted at -3.92, Equity is 7.34 and Total Capital is 2.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.43.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.38 points at the first support level, and at 2.30 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.55, and for the 2nd resistance point, it is at 2.64.

Ratios To Look Out For

To put it in perspective, the Current Ratio for AIM ImmunoTech Inc [AMEX:AIM] is 0.10. As well, the Quick Ratio is 0.10, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 55.33.

Transactions by insiders

Recent insider trading involved Equels Thomas K, CEO & President, that happened on Apr 04 ’25 when 41000.0 shares were purchased. COO, Secretary, Gen. Counsel, Rodino Peter W III completed a deal on Apr 04 ’25 to buy 500.0 shares. Meanwhile, CEO & President Equels Thomas K bought 50000.0 shares on Mar 05 ’25.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.